Gains:
- Understanding why genetic data is a special category of personal data and the risk of re-identification
- Ability to apply anonymization, consent and data minimization principles before providing patient data to open artificial intelligence tools
- Ability to embrace the limits of genetic data processing and professional ethical responsibility within frameworks such as KVKK/GDPR
Genetic data is not ordinary personal data. DNA sequence of a person; It uniquely identifies you, cannot be changed (you can change your password but not your genome), can reveal future disease risks, and concerns not only the individual but all blood-related family members. Therefore, the use of artificial intelligence (AI) when working with genetic data requires the highest standard of confidentiality and ethics. In this unit, you will learn why genetic data must be specially protected, which mistakes have serious consequences when using AI tools, and a safe working discipline.
Critical principle: Never paste identifiable patient genetic data into a publicly available AI tool. Many general-purpose AI services can process the data you enter, store it, or use it to improve the model. When a patient's rare variant combination, name, identification number or date of birth is entered into a tool, an irreversible breach of privacy may occur.
Five features that make genetic data special
- Invariance: The genome is the same throughout life; if disclosed, it cannot be "cancelled".
- Identity: Even a small number of rare variants can uniquely identify a person; Data thought to be "anonymous" can be re-identified.
- Family size: A person's genome also contains the genetic information of their relatives; information may be disclosed without their consent.
- Predictability: Can indicate future disease risk; Insurance may be grounds for employment discrimination.
- Re-identification risk: Genomic data can be linked to identity by crossing with other databases.
Legal framework: a brief overview
Genetic data is in the category of special (sensitive) personal data in data protection legislation and is protected more strictly. In Türkiye, KVKK (Personal Data Protection Law) considers health and genetic data as special data and, as a rule, binds its processing to explicit consent or special exceptions. In Europe, the GDPR similarly protects genetic data as a special category. In the US, the GINA law prohibits insurance and employment discrimination based on genetic information. Although the detail varies by country, the common principle is the same: genetic data cannot be processed without explicit consent, purpose limitation and strong protection.
Tip: When obtaining consent for genetic testing from a patient, disclosure may include how the data will be processed by AI tools. "With what tools and where do we process your data for analysis?" Be in a position to answer the question transparently.
Step by step: using safe AI with secret genetic data
1. Classify. Can the data in your possession be identified? Does it contain a combination of name, ID number, date, rare variant?
2. Anonymize or don't transfer at all. Remove direct identifiers; But remember, "anonymization" in genetic data does not provide full assurance. It is safest not to introduce personally identifiable data into the open vehicle at all.
3. Read the tool's data policy. Choose tools that are corporate, have a data processing agreement (DPA), promise not to use the data in education, and preferably work locally/closely.
4. Separate conceptual questions from data. "How to apply ACMG PM2?" You can ask AI conceptual questions such as; No patient data is required for this. Use data only when necessary and in anonymous form.
5. Save the trace. Document which data you process, with which tool, and for what purpose; Auditability is an ethical and legal requirement.
three mini cases
Case 1 — Pasted report. For speed, an assistant pasted the report containing a patient's full name and variant list into a general AI chat and said "summarize." The senior specialist realized this: the name and rare variant together identified the patient, and the tool stored the data. The incident required a privacy breach notification. Lesson: no identifying data is transferred, even for the summary.
Case 2 — Family consent. While using a patient's data, a researcher told AI that the variant was also found in his sibling. However, the brother did not consent to the processing of his data. The family aspect of genetic data also brought third-party privacy into question; The investigator extracted information about the brother.
Case 3 — Confirmation gained. One laboratory implemented a “anonymization checklist” prior to analysis. They extracted names, ID numbers and dates before giving them to the AI; Moreover, they realized that a very rare combination of variants alone could determine the identity and did not report that sample at all. Without the checklist, data thought to be "anonymous" could have been re-identified.
Four copyable templates
1) Anonymization control:
Before feeding this text to an AI tool, list ALL elements in it (name, ID number, date, address, rare variant combination, rare phenotype) that could identify the patient or their relatives. For each, suggest "omit" or "don't transfer the sample at all": [text].
2) Conceptual question (without data):
WITHOUT sharing patient data, answer this conceptual question: [ACMG/methods question].Use common examples; I don't want real patient information.
3) Consent and transparency control:
Help me draft an information/consent text for genetic testing. It should include: for what purposes the data will be processed, with what types of tools it will be analyzed, how results concerning family members will be handled, storage and deletion. Refer to legal/ethics unit for legal decision.
4) Vehicle selection criteria:
What privacy criteria (data processing agreement, commitment not to use in education, local operation, access control, deletion) should I ask when choosing an AI/analysis tool that will process sensitive genetic data? An evaluation checklist is created.
Weak prompt / Strong prompt
Weak: "Comment Ahmet Yılmaz's (TC: ...) BRCA1 result: [full variant list]."
Problem: Direct identifier + genetic data goes into open tool; gross violation of confidentiality.
Güçlü: "Without identifying anyone, explain using a general example how a frameshift variant in BRCA1 is evaluated at ACMG. I do not share actual patient data."
Why it's powerful: The learning/evaluation need is met, but no identifying data is transferred.
Data type
Does it enter the open AI tool?
alternative
Patient name/identification number
never
No transfer
Rare variant + history
Never (identifies)
Transfer the sample
conceptual question
Yes
General example
Anonymous, common example
careful
Enterprise/local tool
Aggregated, anonymous statistics
depending on the situation
Vehicle with DPA
Common mistakes
- Pasting identifying data as "for summary only". Whatever the purpose, it is a violation.
- Mistaking "anonymization" for genetic data as complete security. Re-identification is possible.
- Forgetting the family aspect. A person's data also reveals their relatives.
- Not reading the vehicle's data policy. The data may be used or stored in training.
- Not keeping track records. If there is no controllability, responsibility cannot be demonstrated.
Caution: Most of the time, privacy violations do not arise from malicious intent, but from a "get it quick" reflex. The biggest risk is mindlessly pasting a report into a chat window in a casual workflow. Slow down; There is no undo button on genetic data.
Depth: the real mathematics of re-identification and secure architectures
Why is it wrong to think "I deleted the name, now it's anonymous"? Because there is no need for a name to identify a person; A combination of rare features is sufficient. According to a classic finding, the trio of date of birth + gender + zip code can single out the vast majority of the US population. In genetics, the situation is sharper: the combination of several rare variants (each occurring at even one in a thousand in the population, together less than one in a million) points to a single individual. Moreover, genomic data can be crossed with genealogy databases to link an individual to the identity of a relative even if the individual has not provided any data anywhere else — a real form of attack that has been demonstrated in the literature.
So preservation requires architectural decisions that go beyond the "delete identifiers" reflex. Practical options: using local/self-hosted models to never leave the data outside the institution's borders; if the cloud will be used, choose enterprise tiers with a data processing agreement (DPA) and a commitment to "not use the input in training"; working with derived, aggregated information rather than patient-specific raw data whenever possible; and limiting access to the principle of least privilege.
Concrete case: a center summarized an “anonymous” case series into a general AI tool. The dataset did not contain names, but each patient had a combination of rare diagnosis + age + city; When crossed with a local newspaper report, a patient could be identified. The absence of raw identifiers did not preclude re-identification.
protection layer
What provides
limit
Identifier deletion
Directly removes ID
Rare combinations remain
Local/self-hosted model
Data does not leave the institution
Installation/maintenance burden
DPA+ not use in education
Legal/contractual assurance
It is necessary to read the policy
Aggregation/derivation
Reduces individual scar
Restricts depth of analysis
In summary
- Genetic data is special, immutable, identifying and family-related data; requires the highest standard of protection.
- Identifiable patient genetic data is never entered into open AI tools; conceptual questions are separated from the data.
- Frameworks such as KVKK, GDPR, GINA require explicit consent, purpose limits and strong protection.
- Anonymization is not complete assurance; The safest thing is not to transfer critical data at all.
Application task
Receive a sample (fictional) genetic report. Using template 1, list all the identifying elements in it and decide whether to “omit” or “no transfer” for each. Then rewrite the same clinical question without any identifying data (using template 2 logic). Describe the privacy difference between the two versions in one sentence.
checklist
- [ ] I classified the data in terms of identity.
- [ ] I did not introduce personally identifiable data into the open tool.
- [ ] I observed that a combination of rare variants could be identified.
- [ ] I checked the tool's data policy (retention, training, DPA).
- [ ] I considered the family aspect and third-party consent.
- [ ] I recorded the transaction trail and forwarded it to the ethics/legal unit when necessary.